# Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

> **NCT06534424** · NA · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 152 (actual)

## Conditions studied

- BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome

## Interventions

- **OTHER:** Best Practice
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Counseling
- **PROCEDURE:** Discussion
- **PROCEDURE:** Genotyping
- **PROCEDURE:** Molecular Risk Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06534424
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06534424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06534424, "Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06534424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*